Accessibility: Skip TopNav
1002-046 (Study 3) Phase 3 Efficacy Study
LDL-C Percent Change from Baseline at 12 weeks
Format
PNG
Source
Esperion Therapeutics, Inc.
Downloads
Original
Large
Medium
Small